All In Biotech

Drug Trial Radar · NCT03192345

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Jun 9, 2017

Primary completion

Dec 21, 2021

Study completion Jan 17, 2022

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: Dose escalation (Part 1) Part 1A (SAR439459 monotherapy) * To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors. Part 1B (SAR439459 and cemiplimab combination therapy) * To determine the MTD and/or MAD of SAR439459 administered intravenously in combination with cemiplimab administered intravenously in adult patients with advanced solid tumors. Dose expansion (Part 2) Part 2A (SAR439459 monotherapy) * To determine optimal dose of SAR439459 administered intravenously in adult patients with advanced melanoma who have failed a prior therapy based on anti-PD-1 (programmed cell death-1) or anti-PD-L1. Part 2B (SAR439459 and cemiplimab combination therapy) * To determine the objective response rate (ORR) of SAR439459 in combination with cemiplimab in adult patients with selected advanced solid tumors by evaluation of antitumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Secondary Objectives: * Pharmacokinetic (PK) profile SAR439459 monotherapy and combined with cemiplimab, PK profile of cemiplimab combined with SAR439459. * Immunogenicity of SAR439459 monotherapy and combined with cemiplimab. Dose escalation (Part 1) * Overall safety/tolerability profile of SAR439459 monotherapy and combined with cemiplimab. * Preliminary recommended phase 2 dose (pRP2D) of SAR439459 as monotherapy or combined with cemiplimab. Dose expansion (Part 2) * Progression free survival (PFS), time to progression (TTP), ORR, and safety of SAR439459 as monotherapy and PFS, TTP, duration of response (DOR), disease control rate (DCR) and safety in combination with cemiplimab. * To confirm the optimal dose of SAR439459 administered in combination with cemiplimab.

Conditions

  • Malignant Solid Tumor

Interventions

  • SAR439459Biological

    Pharmaceutical form: powder for solution for infusion Route of administration: intravenous infusion

  • Cemiplimab REGN2810Drug

    Pharmaceutical form: solution for infusion Route of administration: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Through the end of 1 or 2 cycles, total duration up to 6 weeks (for Part 1A each cycle is 2 weeks; for Part 1B each cycle is 2 or 3 weeks)
  2. Objective Response Rate (ORR) for Part 2BTime frame: Continuous throughout study assessment (up to approximately 1 year)

Locations

34 sites in 13 countries. Site status is shown where the registry gives one.

  • The University of Kansas Clinical Research Center Site Number : 8400004

    Fairway, Kansas

  • Massachusetts General Hospital Site Number : 8400001

    Boston, Massachusetts

  • Dana Farber Cancer Institute Site Number : 8400101

    Boston, Massachusetts

  • Duke University Medical Center Site Number : 8400008

    Durham, North Carolina

  • Tennessee Oncology, PLLC Site Number : 8400006

    Nashville, Tennessee

  • Mary Crowley Cancer Research Center Site Number : 8400003

    Dallas, Texas

  • Investigational Site Number : 0360002

    Heidelberg West, Victoria, Australia

  • Investigational Site Number : 0360001

    Melbourne, Victoria, Australia

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 1240003

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240001

    Toronto, Ontario, Canada

  • Investigational Site Number : 1240002

    Montreal, Quebec, Canada

  • Investigational Site Number : 2330001

    Tallinn, Estonia

  • Investigational Site Number : 2500002

    Marseille, France

  • Investigational Site Number : 2500003

    Nantes, France

  • Investigational Site Number : 2500005

    Nantes, France

  • Investigational Site Number : 2500001

    Villejuif, France

  • Investigational Site Number : 2760001

    Essen, Germany

  • Investigational Site Number : 2760003

    Hanover, Germany

  • Investigational Site Number : 3800001

    Milan, Italy

  • Investigational Site Number : 3800002

    Milan, Italy

  • Investigational Site Number : 3800003

    Rozzano, Milano, Italy

  • Investigational Site Number : 5280001

    Rotterdam, Netherlands

  • Investigational Site Number : 5280002

    Utrecht, Netherlands

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 7240002

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240001

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240003

    Madrid / Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7240004

    Madrid / Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7240005

    Pamplona, Navarre, Spain

  • Investigational Site Number : 1580002

    Tainan, Taiwan

  • Investigational Site Number : 8260001

    Glasgow, Central Bedfordshire, United Kingdom

  • Investigational Site Number : 8260002

    Cardiff, Vale of Glamorgan, the, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.